Designed to address the modeling challenge’s faced by research scientists, Discovery Studio 3.5 is Accelrys’ latest, and most complete modeling and simulation solution for small molecules and macromolecules-based drug design.
Register for our webinar and learn about Discovery Studio’s portfolio of small-molecule ligand design and market-leading biological simulation tools.
|
|
|
|
Biochemical Assays for Screening Workshop
Access the latest Biochemical Screening Technologies
Date: 4 – 6 December 2012
Venue: European ScreeningPort, Hamburg, Germany
European Pharmaceutical Review and European ScreeningPort are pleased to present a unique practical workshop covering the development of biochemical assays for screening purposes.
Taking place over three days at the European ScreeningPort facility in Hamburg, the workshop will offer attendees the chance to participate in practical sessions using the latest technology available from six of the top screening equipment / reagent vendors in the pharmaceutical industry.
Partnered by Thermo Fisher Scientific, PerkinElmer, GE Healthcare, BioTek, Promega and Cisbio Bioassays, this is a must-attend event for anyone in the drug discovery industry to learn about screening technologies and discover what they can do for your company or laboratory.
Find out more >>
|
|
|
|
|
|
|
|
|
|
|
|
Novartis received approval from the European Commission (EC) for Votubia® (everolimus) tablets for the treatment of adult patients with renal angiomyolipoma associated with tuberous sclerosis complex (TSC) who are at risk of complications (based on factors such as tumor size or presence of aneurysm, or presence of multiple or bilateral tumors) but who do not require immediate surgery. This marks the first approval of a medical treatment in this patient population in Europe.
Read full story >>
|
|
 |
|
|
|
|
|
|
Cobalt Light Systems presents RapID, a radically different instrument for RMID that verifies most APIs and excipients through paper, plastic, glass, woven bags, blue barrels and other common pharmaceutical packaging in 5-15 seconds without opening the container. This benefits sterile/parenteral manufacturing and high-volume production by avoiding sampling and contamination. A live presentation on implementing RapID at a manufacturing site is free to attend 19th November 3pm GMT.
Register here >>
|
|
 |
|
|
|
|
|
|
|
|
|
|
Date: Wednesday 14 November 2012
Time: 3pm GMT
Length: 1 hour
Rapid microbial testing methods in quality control continue to gain acceptance in pharmaceutical manufacturing, but most companies continue to use manual, traditional methods. The ability to uncover results in less time than traditional methods provides compelling benefits to manufacturers. These benefits can be realised in environmental monitoring, sterility testing, water and bioburden testing.
Learn from experts where rapid technologies, like the Growth Direct™ System can have an impact on microbial quality control and ultimately manufacturing.
Attendees of the event will learn:
* The limitations of the traditional methods
* The importance of non-destructive testing
* The benefits of automated, rapid detection
Register here >>
|
|
Pharmaceuticals: Global Industry Almanac
The global pharmaceuticals market grew by 3.6% in 2010 to reach a value of $733,104.8 million. In 2015, the global pharmaceuticals market is forecast to have a value of $981,050.8 million, an increase of 33.8% since 2010.
The “Patent Cliff”: How Pfizer has responded to the loss of its best-selling drug
The global pharmaceuticals market was worth $733bn in 2010. With the patents of many of the world’s best-selling drugs expiring, the market is currently in the middle of a “patent cliff”. This Case Study looks at the various routes companies are taking in order to minimize the adverse effects caused by this “patent cliff”.
OTC Pharmaceuticals: Global Industry Almanac 2011
OTC Pharmaceuticals: Global Industry Almanac is an essential resource for top-level data and analysis covering the OTC Pharmaceuticals industry. It includes detailed data on market size and segmentation, textual analysis of the key trends and competitive landscape, and profiles of the leading companies. This incisive report provides expert analysis on a global, regional and country basis.
Johnson & Johnson Case Study: Remicade, a Biotech Blockbuster
Remicade is a drug used in treating a variety of immune system diseases, and its active ingredient is produced through biotechnology. Johnson & Johnson reported Remicade sales of $4.6bn in 2010, and the drug is the best-selling “biologic” in the world. This case study examines its long journey from an academic research laboratory to a leading position in the pharmaceutical market.
|
|
|
IFPAC 2013